Tissue cross-reactivity (TCR) studies are an important aspect of pre-clinical development of therapeutic antibodies. Non-target specific binding to human tissue can result in serious consequences when pharmacologically active antibodies (Ab) are used
to treat diseases. Therefore, prior to Phase I clinical trials, cross-reactivity studies of therapeutic Ab candidates are performed to identify cross-reactive or non-target tissue binding, which in turn provides important information
about the immunological properties of the candidate antibody therapeutics.
Creative Biolabs' TCR services support the development of your candidate therapeutic antibodies by providing a powerful immunohistochemical assessment of potential cross-reactivity with a range of human tissue.
Advanced TCR Service Workflow
Required Starting Materials:
Initiation requirements.
TCR-like antibodies.
Protocol optimization.
Final Deliverables:
Detailed TCR study report.
Data summary of binding sites.
Preclinical safety risk assessment.
Get Customized Services →
Tech Edge
Advanced IHC Systems
Automated platforms ensure high-throughput, reproducible, and precise staining results.
FITC labeling enhances sensitivity, addressing challenges like human-on-human interference.
Tissue Handling
Flexible use of frozen and FFPE tissues ensures accurate antigen preservation.
Advanced preparation techniques maintain integrity for reliable results.
Rigorous Validation
Multi-level validation ensures specificity and reproducibility.
Pre-complexing methods address interference in humanized antibody studies.
Specialized labeling improves detection while maintaining binding accuracy.
High-Res Imaging
Digital imaging provides clear, detailed visualizations for precise analysis.
Quantitative tools support thorough evaluation of binding patterns.
Applications
Oncology
TCR research is also an integral part of Immuno-oncology Assays, as we identify off-target reactions in immune checkpoint inhibitors and other cancer therapies.
Autoimmune Diseases
Identifying cross-reactive immune responses is critical for safe and effective treatments, ensuring minimal unintended activation of immune pathways.
Rare Diseases
In the development of medications for rare diseases, TCR studies address unique safety challenges associated with small and diverse patient populations.
These experiments are required to validate Biologics Testing and assure the targeted delivery of cytotoxic agents in antibody-drug conjugates and other therapeutic platforms.
Publication
A novel mass spectrometry (MS)-based platform was developed to evaluate the cross-reactivity of TCR-like antibodies directly in human tissues. The study confirmed the on-target specificity of a MAGE-A4-targeting antibody while identifying 16 off-target peptides in healthy liver tissue. Structural analysis revealed that these off-target peptides mimic the target's binding motif. This platform identifies physiologically relevant off-targets missed by conventional methods, underscoring the importance of direct tissue-based evaluation to de-risk TCR-like therapeutics before clinical translation.
Fig.1 Structural insights into Fab-mediated cross-reactivity with peptides. 1
Why Choose Us?
Regulatory Excellence
Creative Biolabs adheres to strict guidelines, ensuring every study meets the highest regulatory standards.
Comprehensive Tissue Panels
Our tissue panels include a wide range of human and animal tissues, offering versatility for diverse therapeutic applications.
Innovative IHC Platforms
Automated IHC platforms enhance reproducibility and minimize variability, enabling high-throughput analysis while maintaining accuracy.
Ethical Standards
All tissues are ethically sourced, adhering to informed consent protocols and global ethical guidelines, ensuring integrity in every study.
Tissue Cross-Reactivity Studies are a cornerstone of preclinical therapeutic antibody development, ensuring safety, efficacy, and regulatory compliance. Creative Biolabs, with its innovative methodologies and experienced
team, offers unparalleled solutions to advance your therapeutic pipeline. Contact us to learn more about our services and optimize your antibody development today.
FAQs
What tissues are included in Creative Biolabs’ panels?
Creative Biolabs evaluates 36 tissue types, ensuring a comprehensive analysis. Additional tissues can be included upon request to meet specific client requirements.
What controls are used in TCR studies?
Positive and negative controls are included in every assay to ensure accuracy and reliability. These controls validate the specificity of the antibody binding and minimize false-positive or false-negative results.
What is pre-complexing, and when is it used?
Pre-complexing involves binding the primary and secondary antibodies before applying them to the tissue, reducing interference caused by endogenous human immunoglobulin. It is used for human-on-human staining challenges.
Are the services customizable?
Yes, Creative Biolabs offers fully customizable TCR services. Clients can request additional tissue types, tailored protocols, or enhanced reporting features to suit their project needs.
Can TCR studies predict clinical toxicity?
While not definitive, TCR studies provide critical preclinical insights into potential tissue-specific toxicities. These findings support the design of safer therapeutic antibodies and inform clinical trial strategies.
Customer Review
Resolving Cross-Reactivity Concerns
Using Creative Biolabs' TCR evaluation service in our research has significantly improved the confidence in our lead candidate. The detailed mass spectrometry data allowed us to definitively address a potential cross-reactivity concern that traditional IHC had flagged, saving us months of follow-up work. - J***a B
A Gold Standard for Biologics
The specificity analysis provided by Creative Biolabs was instrumental in our preclinical safety package. The report was thorough, and the team's expertise was evident throughout the process. It's a gold standard for anyone developing novel biologics. - M***k D
How to Contact Us
Creative Biolabs offers a comprehensive suite of services designed to accelerate your biopharmaceutical projects from discovery to the clinic. Our tissue cross-reactivity evaluation service is a critical component of this, providing the safety data and regulatory confidence you need to succeed.
Contact Our Team for More Information and to Discuss Your Project.
Reference
Marrer-Berger, Estelle, et al. "The physiological interactome of TCR-like antibody therapeutics in human tissues." Nature Communications 15.1 (2024): 3271. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41467-024-47062-5
Fig.1 Structural insights into Fab-mediated cross-reactivity with peptides. 1
Immunoassay
Download our brochure